Suchergebnisse - "O'Connor, Owen A"

PubPharm (287)

51

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von O'Connor, O. | Özcan, M. | Jacobsen, E. | +27

52

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Horwitz, S. | O'Connor, O. | Pro, B. | +129

CommentIn: Lancet. 2019 Jan 19;393(10168):201-202. - PMID 30663580

53

Strategy for Assessing New Drug Value in Orphan Diseases : An International Case Match Control Analysis of the PROPEL Study

enthalten in: JNCI cancer spectrum | 2018

von O'Connor, O. | Marchi, E. | Volinn, W. | +3

54

Brentuximab vedotin plus bendamustine : a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

enthalten in: Blood | 2018

von LaCasce, A. | Bociek, R. | Sawas, A. | +14

CommentIn: Blood. 2018 Jul 5;132(1):1-3. - PMID 29976776

55

Tumor Deliverable Iron and Protein Synthesis Inhibitors as a New Class of Drugs for the Diagnosis and Treatment of Cancer

enthalten in: Europäisches Patentamt | 2018

von DENG CHANGCHUN | LIPSTEIN MARK | O'CONNOR OWEN A

56

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma : an open-label, phase 1, dose-escalation, first-in-human study

enthalten in: The Lancet. Oncology | 2018

von Burris, H. | Flinn, I. | Patel, M. | +12

CommentIn: Lancet Oncol. 2018 Apr;19(4):432-434. - PMID 29475725

57

Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma

enthalten in: British journal of haematology | 2018

von Kalac, M. | Lue, J. | Lichtenstein, E. | +9

58

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma : an international, multicentre, single-arm, phase 1-2 trial

enthalten in: The Lancet. Oncology | 2018

von O'Connor, O. | Lue, J. | Sawas, A. | +19

CommentIn: Lancet Oncol. 2018 Feb;19(2):162-163. - PMID 29276023

59

A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma

enthalten in: Blood | 2018

von Amengual, J. | Lichtenstein, R. | Lue, J. | +15

CommentIn: Blood. 2018 Jan 25;131(4):375-376. - PMID 29371206

60

A Case of Bing-Neel Syndrome Successfully Treated with Ibrutinib

enthalten in: Case reports in hematology | 2018

von O'Neil, D. | Francescone, M. | Khan, K. | +4

ErratumIn: Case Rep Hematol. 2018 Oct 29;2018:7610201 Bachir A [corrected to Alobeid B]. - PMID 30510817